SLAMF7 and neoplasm: Two predominantly BCMA−/CS1+ tumor samples recovered from two different animals in the huLuc63-c11D5.3 Short CAR-T-cell-treated group were analyzed by amplicon sequencing, and results indicated that both tumors originated from cells that had been engineered by CRISPR/Cas9 editing to be BCMA− prior to in vivo engraftment (Supplementary Fig. 14 and Supplementary Data File 1).